Rhythm Pharmaceuticals Inc., of Boston, presented phase II results at the Digestive Disease Week conference in Chicago showing that relamorelin, administered twice daily for four weeks in patients with moderate to severe gastroparesis, significantly improved gastric emptying, significantly reduced vomiting and, in a large subgroup (about 60 percent of patients) with vomiting at baseline, significantly improved a composite symptom score comprising nausea, abdominal pain, bloating and early satiety.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST